相似文献
1
Off-label use of anti-IL-1 drugs in rheumatic diseases.
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211006584. doi: 10.1177/20587384211006584.
2
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.
Rheumatology (Oxford). 2015 Dec;54(12):2134-44. doi: 10.1093/rheumatology/kev269. Epub 2015 Jul 23.
3
Actual status of antiinterleukin-1 therapies in rheumatic diseases.
Curr Opin Rheumatol. 2010 May;22(3):246-51. doi: 10.1097/BOR.0b013e3283373fa0.
4
[IL-1 antagonists].
Z Rheumatol. 2010 Sep;69(7):581-93. doi: 10.1007/s00393-009-0530-7.
5
[Current "off label use" of methotrexate for chronic inflammatory rheumatic diseases].
Z Rheumatol. 2011 Feb;70(2):123-8. doi: 10.1007/s00393-010-0685-2.
6
A review on applications of abatacept in systemic rheumatic diseases.
Int Immunopharmacol. 2021 Jul;96:107612. doi: 10.1016/j.intimp.2021.107612. Epub 2021 Apr 3.
7
Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade.
Curr Opin Rheumatol. 2016 May;28(3):197-203. doi: 10.1097/BOR.0000000000000266.
8
Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders.
Clin Exp Rheumatol. 2016 May-Jun;34(3):531-8. Epub 2016 Feb 26.
9
Blocking interleukin-1 in rheumatic diseases.
Ann N Y Acad Sci. 2009 Dec;1182:111-23. doi: 10.1111/j.1749-6632.2009.05159.x.
10
Is interleukin-1 blockade a therapeutic option for patients with palindromic rheumatism?
Clin Rheumatol. 2024 Aug;43(8):2715-2717. doi: 10.1007/s10067-024-07038-8. Epub 2024 Jun 29.
引用本文的文献
1
Targeting the NLRP3 inflammasome as a novel therapeutic target for osteoarthritis.
Inflammopharmacology. 2025 Feb;33(2):461-484. doi: 10.1007/s10787-024-01629-2. Epub 2025 Jan 13.
2
Development of a novel tool for individual treatment trials in mucopolysaccharidosis.
J Inherit Metab Dis. 2025 Jan;48(1):e12816. doi: 10.1002/jimd.12816. Epub 2024 Nov 21.
3
Impaired autophagy in myeloid cells aggravates psoriasis-like skin inflammation through the IL-1β/CXCL2/neutrophil axis.
Cell Biosci. 2024 May 4;14(1):57. doi: 10.1186/s13578-024-01238-0.
4
Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.
Jpn J Clin Oncol. 2024 Apr 6;54(4):365-375. doi: 10.1093/jjco/hyad184.
5
Systematic Review of Roles of Arecoline and Arecoline -Oxide in Oral Cancer and Strategies to Block Carcinogenesis.
Cells. 2023 Apr 21;12(8):1208. doi: 10.3390/cells12081208.
6
Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases.
J Clin Med. 2023 May 4;12(9):3271. doi: 10.3390/jcm12093271.
7
The Role of Neutrophils in Spondyloarthritis: A Journey across the Spectrum of Disease Manifestations.
Int J Mol Sci. 2023 Feb 18;24(4):4108. doi: 10.3390/ijms24044108.
8
Anakinra Pilot - a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants.
Front Immunol. 2022 Oct 27;13:1022104. doi: 10.3389/fimmu.2022.1022104. eCollection 2022.
9
Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors.
Front Oncol. 2022 Oct 31;12:1010660. doi: 10.3389/fonc.2022.1010660. eCollection 2022.
10
Behçet uveitis: Current practice and future perspectives.
Front Med (Lausanne). 2022 Sep 7;9:968345. doi: 10.3389/fmed.2022.968345. eCollection 2022.
本文引用的文献
1
New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy.
Mediators Inflamm. 2020 Jan 17;2020:8294560. doi: 10.1155/2020/8294560. eCollection 2020.
2
Anakinra in Recurrent Pericarditis: Current Evidence on Clinical Use, Effectiveness, and Safety.
J Cardiovasc Pharmacol. 2020 Jul;76(1):42-49. doi: 10.1097/FJC.0000000000000839.
3
Canakinumab for refractory RA: a case report.
Mediterr J Rheumatol. 2018 Sep 27;29(3):170-172. doi: 10.31138/mjr.29.3.170. eCollection 2018 Sep.
4
Severe Late-Onset Kawasaki Disease Successfully Treated With Anakinra.
J Clin Rheumatol. 2020 Mar;26(2):e42-e43. doi: 10.1097/RHU.0000000000000814.
5
Treating osteoarthritis pain: recent approaches using pharmacological therapies.
Clin Exp Rheumatol. 2019 Sep-Oct;37 Suppl 120(5):124-129. Epub 2019 Oct 15.
6
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial.
PLoS Med. 2019 Sep 12;16(9):e1002901. doi: 10.1371/journal.pmed.1002901. eCollection 2019 Sep.
7
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis.
Arthritis Rheumatol. 2020 Feb;72(2):326-334. doi: 10.1002/art.41103. Epub 2019 Dec 26.
8
Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease.
Front Pharmacol. 2019 Aug 23;10:918. doi: 10.3389/fphar.2019.00918. eCollection 2019.
9
IL-1β blockade in periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: case-based review.
Rheumatol Int. 2021 Jan;41(1):183-188. doi: 10.1007/s00296-019-04389-3. Epub 2019 Jul 19.
10
Refractory Sweet Syndrome Treated with Anakinra.
Cureus. 2019 Apr 24;11(4):e4536. doi: 10.7759/cureus.4536.
Zotero 插件